Consequently, about 25% of T-ALL/LBL patients show oncogenic mutations in different members of the JAK and STAT gene families that promote constitutive activation of the JAK/STAT pathway and sustained phosphorylation of STAT5, leading to tumor development11–17. The gene discussed is SOAT1; the disease is acute lymphoblastic leukemia.